Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline

Rodrigo Medeiros, Masashi Kitazawa, Antonella Caccamo, David Baglietto-Vargas, Tatiana Estrada-Hernandez, David H. Cribbs, Avraham Fisher, Frank M. Laferla

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is pathologically characterized by tau-laden neurofibrillary tangles and β-amyloid deposits. Dysregulation of cholinergic neurotransmission has been implicated in AD pathogenesis, contributing to the associated memory impairments; yet, the exact mechanisms remain to be defined. Activating the muscarinic acetylcholine M1 receptors (M1Rs) reduces AD-like pathological features and enhances cognition in AD transgenic models. To elucidate the molecular mechanisms by which M1Rs affect AD pathophysiological features, we crossed the 3xTgAD and transgenic mice expressing human Swedish, Dutch, and Iowa triple-mutant amyloid precursor protein (Tg-SwDI), two widely used animal models, with the M1R-/- mice. Our data show that M 1R deletion in the 3xTgAD and Tg-SwDI mice exacerbates the cognitive impairment through mechanisms dependent on the transcriptional dysregulation of genes required for memory and through acceleration of AD-related synaptotoxicity. Ablating the M1R increased plaque and tangle levels in the brains of 3xTgAD mice and elevated cerebrovascular deposition of fibrillar Aβ in Tg-SwDI mice. Notably, tau hyperphosphorylation and potentiation of amyloidogenic processing in the mice with AD lacking M 1R were attributed to changes in the glycogen synthase kinase 3β and protein kinase C activities. Finally, deleting the M1R increased the astrocytic and microglial response associated with Aβ plaques. Our data highlight the significant role that disrupting the M1R plays in exacerbating AD-related cognitive decline and pathological features and provide critical preclinical evidence to justify further development and evaluation of selective M1R agonists for treating AD.

Original languageEnglish (US)
Pages (from-to)980-991
Number of pages12
JournalAmerican Journal of Pathology
Volume179
Issue number2
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

Muscarinic M1 Receptors
Alzheimer Disease
Pathology
Glycogen Synthase Kinase 3
Cognitive Dysfunction
Neurofibrillary Tangles
Amyloid Plaques
Muscarinic Receptors
Mutant Proteins
Amyloid
Synaptic Transmission
Cognition
Protein Kinase C
Cholinergic Agents
Transgenic Mice
Animal Models

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Medeiros, R., Kitazawa, M., Caccamo, A., Baglietto-Vargas, D., Estrada-Hernandez, T., Cribbs, D. H., ... Laferla, F. M. (2011). Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. American Journal of Pathology, 179(2), 980-991. https://doi.org/10.1016/j.ajpath.2011.04.041

Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. / Medeiros, Rodrigo; Kitazawa, Masashi; Caccamo, Antonella; Baglietto-Vargas, David; Estrada-Hernandez, Tatiana; Cribbs, David H.; Fisher, Avraham; Laferla, Frank M.

In: American Journal of Pathology, Vol. 179, No. 2, 01.08.2011, p. 980-991.

Research output: Contribution to journalArticle

Medeiros, R, Kitazawa, M, Caccamo, A, Baglietto-Vargas, D, Estrada-Hernandez, T, Cribbs, DH, Fisher, A & Laferla, FM 2011, 'Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline', American Journal of Pathology, vol. 179, no. 2, pp. 980-991. https://doi.org/10.1016/j.ajpath.2011.04.041
Medeiros R, Kitazawa M, Caccamo A, Baglietto-Vargas D, Estrada-Hernandez T, Cribbs DH et al. Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. American Journal of Pathology. 2011 Aug 1;179(2):980-991. https://doi.org/10.1016/j.ajpath.2011.04.041
Medeiros, Rodrigo ; Kitazawa, Masashi ; Caccamo, Antonella ; Baglietto-Vargas, David ; Estrada-Hernandez, Tatiana ; Cribbs, David H. ; Fisher, Avraham ; Laferla, Frank M. / Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. In: American Journal of Pathology. 2011 ; Vol. 179, No. 2. pp. 980-991.
@article{fa5fe7555a2c41fd876787563be86ac8,
title = "Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline",
abstract = "Alzheimer's disease (AD) is pathologically characterized by tau-laden neurofibrillary tangles and β-amyloid deposits. Dysregulation of cholinergic neurotransmission has been implicated in AD pathogenesis, contributing to the associated memory impairments; yet, the exact mechanisms remain to be defined. Activating the muscarinic acetylcholine M1 receptors (M1Rs) reduces AD-like pathological features and enhances cognition in AD transgenic models. To elucidate the molecular mechanisms by which M1Rs affect AD pathophysiological features, we crossed the 3xTgAD and transgenic mice expressing human Swedish, Dutch, and Iowa triple-mutant amyloid precursor protein (Tg-SwDI), two widely used animal models, with the M1R-/- mice. Our data show that M 1R deletion in the 3xTgAD and Tg-SwDI mice exacerbates the cognitive impairment through mechanisms dependent on the transcriptional dysregulation of genes required for memory and through acceleration of AD-related synaptotoxicity. Ablating the M1R increased plaque and tangle levels in the brains of 3xTgAD mice and elevated cerebrovascular deposition of fibrillar Aβ in Tg-SwDI mice. Notably, tau hyperphosphorylation and potentiation of amyloidogenic processing in the mice with AD lacking M 1R were attributed to changes in the glycogen synthase kinase 3β and protein kinase C activities. Finally, deleting the M1R increased the astrocytic and microglial response associated with Aβ plaques. Our data highlight the significant role that disrupting the M1R plays in exacerbating AD-related cognitive decline and pathological features and provide critical preclinical evidence to justify further development and evaluation of selective M1R agonists for treating AD.",
author = "Rodrigo Medeiros and Masashi Kitazawa and Antonella Caccamo and David Baglietto-Vargas and Tatiana Estrada-Hernandez and Cribbs, {David H.} and Avraham Fisher and Laferla, {Frank M.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1016/j.ajpath.2011.04.041",
language = "English (US)",
volume = "179",
pages = "980--991",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline

AU - Medeiros, Rodrigo

AU - Kitazawa, Masashi

AU - Caccamo, Antonella

AU - Baglietto-Vargas, David

AU - Estrada-Hernandez, Tatiana

AU - Cribbs, David H.

AU - Fisher, Avraham

AU - Laferla, Frank M.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Alzheimer's disease (AD) is pathologically characterized by tau-laden neurofibrillary tangles and β-amyloid deposits. Dysregulation of cholinergic neurotransmission has been implicated in AD pathogenesis, contributing to the associated memory impairments; yet, the exact mechanisms remain to be defined. Activating the muscarinic acetylcholine M1 receptors (M1Rs) reduces AD-like pathological features and enhances cognition in AD transgenic models. To elucidate the molecular mechanisms by which M1Rs affect AD pathophysiological features, we crossed the 3xTgAD and transgenic mice expressing human Swedish, Dutch, and Iowa triple-mutant amyloid precursor protein (Tg-SwDI), two widely used animal models, with the M1R-/- mice. Our data show that M 1R deletion in the 3xTgAD and Tg-SwDI mice exacerbates the cognitive impairment through mechanisms dependent on the transcriptional dysregulation of genes required for memory and through acceleration of AD-related synaptotoxicity. Ablating the M1R increased plaque and tangle levels in the brains of 3xTgAD mice and elevated cerebrovascular deposition of fibrillar Aβ in Tg-SwDI mice. Notably, tau hyperphosphorylation and potentiation of amyloidogenic processing in the mice with AD lacking M 1R were attributed to changes in the glycogen synthase kinase 3β and protein kinase C activities. Finally, deleting the M1R increased the astrocytic and microglial response associated with Aβ plaques. Our data highlight the significant role that disrupting the M1R plays in exacerbating AD-related cognitive decline and pathological features and provide critical preclinical evidence to justify further development and evaluation of selective M1R agonists for treating AD.

AB - Alzheimer's disease (AD) is pathologically characterized by tau-laden neurofibrillary tangles and β-amyloid deposits. Dysregulation of cholinergic neurotransmission has been implicated in AD pathogenesis, contributing to the associated memory impairments; yet, the exact mechanisms remain to be defined. Activating the muscarinic acetylcholine M1 receptors (M1Rs) reduces AD-like pathological features and enhances cognition in AD transgenic models. To elucidate the molecular mechanisms by which M1Rs affect AD pathophysiological features, we crossed the 3xTgAD and transgenic mice expressing human Swedish, Dutch, and Iowa triple-mutant amyloid precursor protein (Tg-SwDI), two widely used animal models, with the M1R-/- mice. Our data show that M 1R deletion in the 3xTgAD and Tg-SwDI mice exacerbates the cognitive impairment through mechanisms dependent on the transcriptional dysregulation of genes required for memory and through acceleration of AD-related synaptotoxicity. Ablating the M1R increased plaque and tangle levels in the brains of 3xTgAD mice and elevated cerebrovascular deposition of fibrillar Aβ in Tg-SwDI mice. Notably, tau hyperphosphorylation and potentiation of amyloidogenic processing in the mice with AD lacking M 1R were attributed to changes in the glycogen synthase kinase 3β and protein kinase C activities. Finally, deleting the M1R increased the astrocytic and microglial response associated with Aβ plaques. Our data highlight the significant role that disrupting the M1R plays in exacerbating AD-related cognitive decline and pathological features and provide critical preclinical evidence to justify further development and evaluation of selective M1R agonists for treating AD.

UR - http://www.scopus.com/inward/record.url?scp=80052479573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052479573&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2011.04.041

DO - 10.1016/j.ajpath.2011.04.041

M3 - Article

C2 - 21704011

AN - SCOPUS:80052479573

VL - 179

SP - 980

EP - 991

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 2

ER -